Zhejiang Smile-youth Medical Technology Co., Ltd., affiliated with WENZHOU CELECARE MEDICAL INSTRUMENTS Co., Ltd (Note: Revised to standard corporate abbreviation format), is a comprehensive beauty and medical integrated company registered with a capital of RMB 10 million. It primarily promotes medical-grade hydrocolloid materials produced by its parent company, CELECARE. The parent company, CELECARE, specializes in the R&D, production, sales, and service of medical devices. With a registered capital of RMB 6.294 million and over 100 employees, it exports to the United States, India, the United Kingdom, France, South Korea, Turkey, Russia, South Africa, South American countries, the Middle East, and other regions. CELECARE has been dedicated to advancing in the medical device field since its establishment in December 2009. Starting with a single medical hydrocolloid product, it now offers over a dozen Class I and II medical device varieties, ranking among the top three in China. The company holds multiple patents and maintains an independent R&D team with proprietary designs.

Over its 13-year history, CELECARE has established partnerships with more than 1, 000 stable clients nationwide. In 2013, the company relocated to the National University Science Park for expansion. By October 2015, it completed and operationalized a new factory at No. 2 Dapeng Road, spanning over 3, 000 square meters. The facility includes a 1, 200-square-meter production workshop and quality inspection laboratory, featuring 500+ square meters of clean production areas, a 100+ square-meter sterile laboratory, and over a dozen large-scale production machines alongside 20+ specialized testing instruments.

CELECARE has participated in domestic and international industry exhibitions in Guangzhou, Shanghai, and other cities, earning recognition for its flagship products. Core product lines include ostomy care, phototherapy protection, and wound dressing series. The company currently employs 100+ staff, including a 5-member design team and 2 postgraduate/doctoral researchers. It continues to innovate and expand its product portfolio.

By 2025, a new 40, 000+ square meter integrated facility will be completed, housing production, R&D, laboratories, exhibition halls, procurement, sales, warehousing, staff dormitories, and recreational zones. This expansion aims to enhance service quality for global clients.

Guided by a professional healthcare management philosophy, the company strives to deliver superior medical products and services, exceeding customer expectations and advancing value-driven innovation.